You are here: Industry Insights > Osteoporosis

News List

Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab) worldpharmanews
January 21, 2019
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab)
EVENITY (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture firstwordpharma
January 09, 2019
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fr
EVENITY (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture firstwordpharma
January 09, 2019
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fr
Could a once-abandoned obesity drug be revived in osteoporosis? fiercebiotech
December 26, 2018
Irisin, the once much-hyped but controversial “exercise hormone” that researchers had hoped would be an effective obesity treatment, could make a comeback—this time in bone strengthening.
Younger Breast Cancer Survivors Suffer More Bone Loss From Treatment drugs
December 12, 2018
Younger breast cancer survivors are at increased risk for osteoporosis -- weak, brittle bones -- due to breast cancer treatments, new study finds.....
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture firstwordpharma
December 02, 2018
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVE
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture firstwordpharma
December 02, 2018
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVE
UCB, Amgen refile osteoporosis drug Evenity pharmatimes
July 17, 2018
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
Promoting blood vessel growth in bone could treat osteoporosis fiercebiotech
May 29, 2018
The drugs that are on the market to treat osteoporosis work by either blocking cells that break down bone or by boosting osteoblasts—the cells that build bone.
Promoting blood vessel growth in bone could treat osteoporosis fiercebiotech
May 28, 2018
The drugs that are on the market to treat osteoporosis work by either blocking cells that break down bone or by boosting osteoblasts—the cells that build bone.

Previous page 1 2 3 4 Next page